| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Mannkind Corporation |
| Information provided by: | Mannkind Corporation |
| ClinicalTrials.gov Identifier: | NCT00673621 |
Purpose
This study will compare the rate and extent of absorption of TI Inhalation Powder in subjects with asthma and subjects with normal lung function. 24 eligible subjects will be enrolled into the treatment phase of the trial.
| Condition | Intervention | Phase |
|
Asthma Diabetes Mellitus |
Drug: Technosphere Insulin Inhalation Powder Drug: Salbutamol (Albuterol) Drug: Methacholine chloride |
Phase I |
| MedlinePlus related topics: | Asthma Diabetes |
| Drug Information available for: | Insulin Sodium chloride Albuterol sulfate Albuterol Levalbuterol hydrochloride Levalbuterol tartrate Chlorides Methacholine Methacholine chloride |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Pharmacokinetics Study |
| Official Title: | A Phase 1, Open-Label, Controlled Clinical Trial to Evaluate Pharmacokinetics After Administration of Technosphere® Insulin Inhalation Powder Alone and With Salbutamol (Albuterol) and/or After Methacholine Challenge Testing in Subjects With Asthma Versus Matched Healthy Subjects Without Asthma |
| Estimated Enrollment: | 24 |
| Study Start Date: | May 2008 |
| Estimated Study Completion Date: | November 2008 |
| Estimated Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
| 1: Experimental |
Drug: Technosphere Insulin Inhalation Powder
3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
Drug: Salbutamol (Albuterol)
2 puff = 200 mcg total dose
Drug: Methacholine chloride
5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
|
Visit 1 screening will determine eligibility and obtain informed consent. At visit 2, 3 and 4 subjects inhale 1 dose of 45U TI Inhalation Powder. At visit 3 subjects inhale 2 puffs (200mcg) Albuterol prior to dosing. Only asthmatic subjects undergo visit 4 where a methacholine challenge test (MCT) is performed followed by inhalation of Albuterol then administration of TI Inhalation Powder. Each visit's dosing will occur during a hyperinsulinemic euglycemic clamp. Visit 5 is the follow up visit.
Eligibility
| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Non smoking male and female subjects = 18 and = 55 years of age with BMI = 34 kg/m2 Fasting blood glucose (FBG) < 110 mg/dL (6.1 mmol/L). Written informed consent Asthmatic Subjects: Clinical diagnosis of asthma along with defined reversibility from pre- to post-bronchodilator spirometry.
Pulmonary Function Testing for Asthmatic subjects: FEV1 > 70% (NHANES III), TLC >70% (ITS), Dlco >80% (Miller) Non-asthmatic healthy subjects: FEV1 > 80% (NHANES III), FEV1/FVC > LLN (NHANES), TLC >80% (ITS), Dlco >80% (Miller), no significant improvement from pre- to post-bronchodilator spirometry.
Exclusion Criteria:
Unable and/or unlikely to comprehend how to use the investigational device in this study or to follow study instructions Change in asthma therapeutic regimen from Screening through visit 5 Exacerbation of asthma within 8 weeks prior to Screening History of diabetes mellitus Previous exposure to any inhaled insulin product other than TI inhalation Powder or similar formulation Inability to perform PFT maneuvers meeting recommended American Thoracic Society (ATS) standards of acceptability and repeatability criteria Any clinically important pulmonary disease Major organ system diseases including seizures, heart failure, uncontrolled hypertension, cancer within the past 5 years, aneurysm, liver disease, anemia or autoimmune disorder Clinically significant abnormalities on screening laboratory evaluation Female subjects who are pregnant, lactating, or planning to become pregnant during the clinical trial period or not practicing adequate birth control
Contacts and Locations| United Kingdom | |||||
| ICON Development Solutions | Recruiting | ||||
| Manchester, United Kingdom, M15 6SH | |||||
| Contact: Cyril Clarke, Dr 011441612322723 | |||||
| United Kingdom, England | |||||
| Medicines Evaluation Unit (MEU) | Recruiting | ||||
| Manchester, England, United Kingdom, M23 9QZ | |||||
| Contact: Dave Singh, Dr +44 (0)161 946 4050 | |||||
| Mannkind Corporation |
| Study Chair: | Anders H. Boss | Mannkind Corporation |
More Information
| Responsible Party: | MannKind Corporation ( Anders H. Boss. MFPM ) |
| Study ID Numbers: | MKC-TI-113 |
| First Received: | May 5, 2008 |
| Last Updated: | September 22, 2008 |
| ClinicalTrials.gov Identifier: | NCT00673621 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|
